KEI Comments to the NIH Regarding Prospective Exclusive License to UK firm Mevox

On June 2, 2021, Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development, Commercialization, and Use of Protein-Based Vaccines Expressing Recombinant Measles and Mumps Immunogens for… Continue Reading

COVID-19 Vaccine Manufacturing Capacity

KEI has created a public listserve to discuss vaccine manufacturing scale up. (link) February 19, 2021: Roundtable on Pathways to Scale Up Manufacturing Capacity for COVID-19 Vaccines – 19. KEI has gathered data regarding vaccine manufacturing capacity in countries worldwide,… Continue Reading

2019: Joint Comments on NIH Prospective License to Medigen on RSV and Parainfluenza Vaccines (and NIH Response)

(UPDATE: The NIH provided a response to our comments on February 4, 2019) On January 7, 2019, KEI and MSF (Doctors Without Borders/Médecins Sans Frontières USA) submitted comments to the Federal Register notice (83 FR 65696) on the “Prospective Grant… Continue Reading